News Release

Blackhawk Growth Establishes Monthly Revenue Record of $501,000

By February 4, 2021 No Comments

Vancouver, British Columbia – TheNewswire – February 4, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (Frankfurt:0JJ) (OTC:BLRZF) (the “Company”), is pleased to announce gross revenue for the month of January 2021 of approximately CDN$501,000. Revenue has increased by approximately 30% from the month of December 2020. This record revenue level is a continuation of successful execution by a number of the Blackhawk portfolio companies.

For January 2021, Noble Line reported unaudited gross revenue of CDN$353,000, this is a 44% increase over the revenue generated in the month of December 2020.

Sac Pharma also continues to show significant results with unaudited gross revenue for the month of January 2021 of CDN$148,000.

Through the remainder of the first quarter of 2021, the Company anticipates continued revenue growth from Noble Line and Sac Pharma, as well as the following portfolio companies revenue coming on stream. Spaced Food, which is expected to receive product approval and begin commercial production. LeichtMind clinic in Alberta, as part of Trip Pharma’s operations, has begun to treat patients in its Edmonton location. Sales of the test kits will continue as the company expands in the US.

Blackhawk is also happy to announce that in January it received full settlement on the $90,000 loan that had been outstanding since 2019. The settlement was accomplished through the receipt of both publicly tradable shares and warrants from the debtor.

The Company cautions that figures for revenue and margin generated by the Company have not been audited and are based on calculations prepared by management.  Actual results may differ from those reported in this release once these figures have been audited.

 

About Blackhawk Growth

 

Blackhawk Growth is an investment issuer looking to create substantial value for our shareholders through the acquisition and development of high growth opportunities. The company has focused its investments in the health, cannabis and CBD industries in both Canada and the United States. Its portfolio of companies include Sac Pharma, Trip Pharma, Noble Hemp, Spaced Food and NuWave Foods.

For more information on Blackhawk, please visit our website at:

https://www.blackhawkgrowth.com/

Frederick Pels, Chief Executive Officer

(403)-991-7737

[email protected]blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

 

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the future prospects of the business of the Company and its portfolio companies. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.